Scilex Holding Company $SCLX Position Trimmed by State of Wyoming

Key Points

• The State of Wyoming reduced its holdings in Scilex Holding Company ($SCLX) by 8.1%, now owning 131,139 shares worth approximately $33,000.
• Jane Street Group LLC significantly increased its stake in Scilex by 965.8% in the fourth quarter, now holding 321,480 shares valued at $137,000.
• Scilex reported a quarterly earnings loss of ($7.42) EPS, missing estimates, with revenue of $9.90 million compared to a consensus of $26.25 million.

State of Wyoming lowered its holdings in shares of Scilex Holding Company (NASDAQ:SCLX - Free Report) by 8.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,139 shares of the company's stock after selling 11,485 shares during the quarter. State of Wyoming owned approximately 1.89% of Scilex worth $33,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Jane Street Group LLC lifted its holdings in Scilex by 965.8% during the 4th quarter. Jane Street Group LLC now owns 321,480 shares of the company's stock valued at $137,000 after buying an additional 291,316 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Scilex by 28.7% in the fourth quarter. Janus Henderson Group PLC now owns 687,547 shares of the company's stock worth $293,000 after purchasing an additional 153,245 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Scilex by 64.0% during the 4th quarter. Northern Trust Corp now owns 1,273,968 shares of the company's stock valued at $543,000 after purchasing an additional 497,182 shares in the last quarter. 69.67% of the stock is owned by institutional investors.

Scilex Price Performance

SCLX traded up $0.92 on Friday, reaching $26.28. 342,895 shares of the company's stock were exchanged, compared to its average volume of 213,275. The stock has a market cap of $182.91 million, a PE ratio of -0.91 and a beta of 1.34. The stock's fifty day moving average price is $15.24 and its 200-day moving average price is $9.72. Scilex Holding Company has a twelve month low of $3.60 and a twelve month high of $41.30.

Scilex (NASDAQ:SCLX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($7.42) EPS for the quarter, missing the consensus estimate of ($4.55) by ($2.87). The business had revenue of $9.90 million for the quarter, compared to analyst estimates of $26.25 million. As a group, research analysts predict that Scilex Holding Company will post -0.57 earnings per share for the current fiscal year.

About Scilex

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.